Published on: April 2026
INTEGRATING BIOMARKERS INTO ONCOLOGY: A NEW ERA IN CARDIOTOXICITY MONITORING
Zaffar Iqbal Sahil Farooq
Isha Dhiman1*, Jeewanjot Singh
Article Status
Available Documents
Abstract
Cancer and cardiovascular disease are the leading causes of mortality worldwide, and advancements in cancer therapy have significantly improved patient survival. However, many anticancer treatments including chemotherapy, radiotherapy, targeted therapies, and immune checkpoint inhibitors are associated with a wide range of cardiovascular toxicities such as heart failure, coronary artery disease, myocarditis, arrhythmias, and venous thromboembolism. Biomarkers have emerged as valuable tools in the diagnosis, risk stratification, and monitoring of cardiovascular disease in cancer patients. Established biomarkers such as cardiac troponins and natriuretic peptides (BNP and NT-proBNP) play a key role in identifying myocardial injury and cardiac dysfunction. Additionally, D-dimer is widely used in the assessment of thrombotic risk. This review summarizes the current understanding of cardiovascular biomarkers in the context of cancer therapy-induced cardiotoxicity, highlighting their role in heart failure, acute coronary syndromes, myocarditis, and venous thromboembolism.
How to Cite this Paper
Iqbal, Z. & Farooq, S. (2026). Integrating Biomarkers into Oncology: A New Era in Cardiotoxicity Monitoring. International Journal of Creative and Open Research in Engineering and Management, <i>02</i>(04). https://doi.org/10.55041/ijcope.v2i4.454
Iqbal, Zaffar, and Sahil Farooq. "Integrating Biomarkers into Oncology: A New Era in Cardiotoxicity Monitoring." International Journal of Creative and Open Research in Engineering and Management, vol. 02, no. 04, 2026, pp. . doi:https://doi.org/10.55041/ijcope.v2i4.454.
Iqbal, Zaffar, and Sahil Farooq. "Integrating Biomarkers into Oncology: A New Era in Cardiotoxicity Monitoring." International Journal of Creative and Open Research in Engineering and Management 02, no. 04 (2026). https://doi.org/https://doi.org/10.55041/ijcope.v2i4.454.
Search & Index
References
- A. Alshahrani, E. Kontopantelis, C. Morgan, R. Ravindrarajah, G. P. Martin, and M. A. Mamas, "Cardiovascular diseases in patients with cancer: A comprehensive review of epidemiological trends, cardiac complications, and prognostic implications," (in eng), Chin Med J (Engl), vol. 138, no. 2, pp. 143-154, Jan 20 2025, doi: 10.1097/cm9.0000000000003419.
- [2] W. J. Hucker, Y. S. Chatzizisis, M. L. Steigner, G. L. Winters, and J. M. Kirshenbaum, "Myocardial catastrophe: a case of sudden, severe myocardial dysfunction," (in eng), Circulation, vol. 130, no. 10, pp. 854-62, Sep 2 2014, doi: 10.1161/circulationaha.113.007417.
- [3] R. K. Upadhyay, "Emerging risk biomarkers in cardiovascular diseases and disorders," (in eng), J Lipids, vol. 2015, p. 971453, 2015, doi: 10.1155/2015/971453.
- [4] V. Castiglione, A. Aimo, G. Vergaro, L. Saccaro, C. Passino, and M. Emdin, "Biomarkers for the diagnosis and management of heart failure," (in eng), Heart Fail Rev, vol. 27, no. 2, pp. 625-643, Mar 2022, doi: 10.1007/s10741-021-10105-w.
- [5] R. Sarzani, M. Allevi, C. Di Pentima, P. Schiavi, F. Spannella, and F. Giulietti, "Role of Cardiac Natriuretic Peptides in Heart Structure and Function," (in eng), Int J Mol Sci, vol. 23, no. 22, Nov 20 2022, doi: 10.3390/ijms232214415.
- [6] T. Nishikimi and Y. Nakagawa, "B-Type Natriuretic Peptide (BNP) Revisited-Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era?," (in eng), Biology (Basel), vol. 11, no. 7, Jul 9 2022, doi: 10.3390/biology11071034.
- [7] A. Bayes-Genis et al., "Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC," (in eng), Eur J Heart Fail, vol. 25, no. 11, pp. 1891-1898, Nov 2023, doi: 10.1002/ejhf.3036.
- [8] M. Volpe, G. Gallo, and S. Rubattu, "Endocrine functions of the heart: from bench to bedside," (in eng), Eur Heart J, vol. 44, no. 8, pp. 643-655, Feb 21 2023, doi: 10.1093/eurheartj/ehac759.
- [9] D. Gruson et al., "The multidimensional value of natriuretic peptides in heart failure, integrating laboratory and clinical aspects," (in eng), Crit Rev Clin Lab Sci, vol. 61, no. 6, pp. 458-472, Sep 2024, doi: 10.1080/10408363.2024.2319578.
- [10] E. N. M. Salerno et al., "GLP1-RAs: long-term use versus discontinuation events of an emerging therapy for obesity and cardiovascular diseases," (in eng), Curr Probl Cardiol, vol. 51, no. 2, p. 103213, Feb 2026, doi: 10.1016/j.cpcardiol.2025.103213.
Ethical Compliance & Review Process
- •All submissions are screened under plagiarism detection.
- •Review follows editorial policy.
- •Authors retain copyright.
- •Peer Review Type: Double-Blind Peer Review
- •Published on: Apr 18 2026
This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. You are free to share and adapt this work for non-commercial purposes with proper attribution.